ICL (ICL) Q2 2026 Earnings Call Transcript

ICL Group reported Q2 sales of $2.1B (+17% YoY) and adjusted EBITDA of $448M (+28% YoY), driving adjusted EPS to $0.12 (+33%) despite ~$100M higher raw material costs. The company reiterated 2026 consolidated EBITDA guidance of $1.5B–$1.7B while warning that sulfur costs (up 72% sequentially, >210% YoY) and freight (up ~45%) should pressure phosphate margins in 2H, along with Brazil softness. ICL continues its “Elevate” cost program targeting >$150M annual EBITDA improvement by end-2027 and >$350M by end-2028, and maintained shareholder returns with a $75M dividend (50% payout; trailing 12-month yield 4.1%) after completing an $800M senior notes offering.

Analysis

ICL screens as a modestly better-quality fertilizer/industrial hybrid than the market usually gives it credit for, but the quarter does not justify paying up aggressively here. The important mechanism is mix: bromine and specialty/pharma/food ingredients are offsetting what is still a very cyclical ag-input base, so the stock should trade more like a diversified chemical asset than a pure potash name if management executes on the segment reset.

Near term, the bigger driver is not headline EBITDA but the spread between selling prices and three cost lines: sulfur, freight, and FX. Those inputs can squeeze phosphate and specialty crops for multiple quarters, so even if reported volumes hold, margin expansion is not linear into H2; that makes the next 1-2 earnings prints more important than the call itself. A stronger shekel would be the cleanest falsifier because it hits a large dollar-cost base without an offset on demand.

The contrarian read is that consensus may be too focused on the cost headwinds and missing the embedded option value in industrial bromine and food ingredients. Those businesses could re-rate the multiple if investors believe the 2027 reporting change reveals a higher-margin, less agricultural mix; however, that is a 6-18 month story, not a catalyst for chasing the stock tomorrow. If sulfur normalizes or Brazil improves, the stock likely has another leg up; if not, the current guidance range may prove too optimistic for the back half.

Relative losers are the more exposed phosphate and specialty-fertilizer peers with less industrial offset, while winners are any supply-chain beneficiaries of sustained bromine scarcity and AI/electronics-related specialty demand. The risk/reward is therefore better for a relative-value expression than for a naked directional bet.

Key Decisions for Investors

• Add ICL on pullbacks only; use it as a 6-12 month quality/optionality hold rather than a chase-the-print name. Risk/reward is acceptable if the stock remains below the market's implied multiple for diversified specialty chemicals, but fade strength if sulfur stays elevated into the next quarter.
• Pair trade: long ICL / short MOS over the next 1-3 months. ICL has more visible industrial bromine and specialty-food optionality, while MOS remains more levered to phosphate input-cost inflation; thesis breaks if bromine normalizes sharply or sulfur/freight ease faster than expected.
• Avoid aggressive call buying until the next quarterly update confirms that Elevate is translating into cash flow, not just rhetoric. If you want upside exposure, consider a small long-dated call spread in ICL for 6-12 months, but only if the stock fails to rerate on the next print.
• Set an alert on USD/ILS and sulfur prices as the key falsifiers over the next 1-2 quarters. A sustained stronger shekel or another leg higher in sulfur would likely cap EBITDA and invalidate any near-term bull case.
• Watch for a relative-value long in ICL versus a basket of pure ag input names if Brazil stays soft. The stock should outperform lower-quality fertilizer exposures if management proves it can preserve margins through product mix and cost actions.